Study:
A Phase III Trial Of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed By Maintenance Therapy With ZD 1839 Or Placebo In Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor
cells. Biological therapies such as gefitinib may interfere with the growth of the tumor
cells and slow the growth of tumors. It is not yet known whether combination chemotherapy
plus radiation therapy is more effective with or without gefitinib in treating non-small
cell lung cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of combination chemotherapy
plus radiation therapy with or without gefitinib in treating unresectable stage III
non-small cell lung cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Drug: ZD-1839
Radiation: radiation therapy
Drug: placebo |
Phase 3 |
Verified by
National Cancer Institute (NCI)
October, 2012
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00020709
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States
Karen Kelly, MD., Study Chair
James R. Jett, MD., Study Chair
Yee C. Ung, MD, FRCPC., Study Chair